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ABSTRACT
Growth and differentiation factor 15 (GDF- 15), also known as macrophage inhibi-
tory cytokine 1 (MIC- 1), may act as both a tumor suppressor and promotor and, by 
regulating NF- κB and macrophage signaling, promote early prostate carcinogenesis. 
To determine whether expression of these two inflammation- related proteins affect 
prostate cancer susceptibility, dual immunostaining of benign prostate biopsies for 
GDF- 15 and NF- κB was done in a study of 503 case- control pairs matched on date, 
age, and race, nested within a historical cohort of 10,478 men. GDF- 15 and NF- κB 
expression levels were positively correlated (r = 0.39; p < 0.0001), and both were 
significantly lower in African American (AA) compared with White men. In adjusted 
models that included both markers, the odds ratio (OR) for NF- κB expression was 
statistically significant, OR =0.87; p = 0.03; 95% confidence interval (CI) =0.77– 
0.99, while GDF- 15 expression was associated with a nominally increased risk, 
OR =1.06; p = 0.27; 95% CI =0.96– 1.17. When modeling expression levels by quar-
tiles, the highest quartile of NF- κB expression was associated with almost a fifty 
percent reduction in prostate cancer risk (OR =0.51; p = 0.03; 95% CI =0.29– 0.92). 
In stratified models, NF- κB had the strongest negative association with prostate can-
cer in non- aggressive cases (p = 0.03), older men (p = 0.03), and in case- control 
pairs with longer follow- up (p = 0.02). Risk associated with GDF- 15 expression was 
best fit using nonlinear regression modeling where both first (p = 0.02) and second 
(p = 0.03) order GDF- 15 risk terms were associated with significantly increased risk. 
This modeling approach also revealed significantly increased risk associated with 
GDF- 15 expression for subsamples defined by AA race, aggressive disease, younger 
age, and in case- control pairs with longer follow- up. Therefore, although positively 
correlated in benign prostatic biopsies, NF- κB and GDF- 15 expression appear to exert 
opposite effects on risk of prostate tumor development.
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1 |  INTRODUCTION
Chronic inflammation is thought to increase cancer risk,1 
and multiple lines of evidence support a link between chronic 
prostatic inflammation and prostate cancer development.2 
Most prostate surgical specimens show histologic signs 
of inflammation,3,4 and several studies from the Prostate 
Prevention Trial Cohort suggest prostatic inflammation in-
creases prostate cancer risk.4,5 However, a growing body of 
evidence from men with benign biopsies followed for subse-
quent prostate cancer suggests that histologic inflammation 
may decrease prostate cancer risk.6- 9 Although several stud-
ies have investigated associations between multiple circulat-
ing inflammatory markers and prostate cancer risk,10- 12 no 
previous study has, to our knowledge, evaluated the associa-
tion between pre- diagnostic histologic markers of inflamma-
tion in the prostate and subsequent risk of cancer.
The inflammatory prostate tumor microenvironment in-
cludes leukocytes, cytokines, and complement components, 
all orchestrated by transcription factors. Nuclear factor 
kappa- light- chain- enhancer of activated B cells, NF- κB, is a 
transcription factor that regulates pro- inflammatory gene ex-
pression and is constitutively activated in castration- resistant 
prostate cancer.13 Prostatic epithelial cells may play a signif-
icant role in sustaining and amplifying inflammation through 
NF- κB activation and local production of proinflammatory 
cytokines that result in the recruitment and activation of addi-
tional immune cells in the prostate.14 In the benign prostate, 
NF- κB expression has been shown to be positively correlated 
with presence of histologic inflammation but not inflamma-
tion grade.15 The NF- κB protein consists of homodimers and 
heterodimers formed from five subunits (p65, c- rel, RelB, 
p50, and p52). In the canonical pathway, the inactive form 
of the p65/p50 dimer is associated with the inhibitor IκB and 
is retained in the cytoplasm.16 Once phosphorylated, IκB re-
leases the p65/p50 dimer which then translocates to the nu-
cleus activating the NF- κB signaling pathways that can result 
in the progression of prostate cancer.17 In the pre- malignant 
prostate, expression of the NF- κB p65 subunit is more prom-
inent in prostates with benign hyperplasia and expressed pri-
marily in basal cells and cytoplasm.18,19
Growth differentiation factor 15 (GDF- 15), also called 
prostate- derived factor or PDF, NAG- 1, or MIC- 1, is a 
stress- induced anti- inflammatory cytokine expressed in 
macrophages, vascular smooth muscle cells, cardiomyo-
cytes, adipocytes, and endothelial cells.20 GDF- 15 is not only 
expressed in prostate cancer but also in the prostatic pre- 
malignant inflammatory environment.21 GDF- 15 possesses 
immunomodulatory functions22 and appears to have a key role 
in regulating inflammatory pathways in prostate, exhibiting 
both tumor- suppressing and tumor- promoting functions.23 
GDF- 15 may suppress the activity of NF- κB, indicating a 
tumor- suppressing quality, but has also been shown to prefer-
entially inhibit M1 macrophage formation, indicating a pro- 
tumorigenic quality.24 Conversely, recent evidence from in 
vitro and in vivo pancreatic cancer models suggests that NF- 
κB regulates GDF- 15, which in turn signals macrophages to 
suppress their proapoptotic activity thereby stimulating early 
cancer development.25 Data from prostate cancer immuno-
histochemical analyses indicate that NF- κB and GDF- 15 are 
overexpressed in prostate tumor as compared to benign adja-
cent and normal prostatic tissues and overexpressed in bone 
metastasis specimens from patients.26
Given the complexity of the immune system network and 
the multidimensionality of host- tumor interactions, NF- κB 
and GDF- 15 may be signature molecules that can elucidate 
the molecular kinetics of inflammatory responses early in 
prostatic carcinogenesis. To evaluate the role of NF- κB and 
GDF- 15 in early prostate cancer development, we studied the 
prostate cancer risk associated with the expression of these 
two molecules in benign prostatic biopsies from a matched 
case- control sample nested within a large retrospective co-
hort of men with a benign biopsy testing models stratified by 
race and other case characteristics.
2 |  MATERIALS AND METHODS
2.1 | Study sample
After Institutional Review Board approval, we identified a 
historical cohort of 10,478 men with a benign specimen col-
lected by needle core biopsy of the prostate between January 
1990 and December 2012. Within this cohort, a nested case- 
control sample was assembled. Eligibility criteria included a 
recorded PSA level within a year of cohort entry, no history 
of a previous prostate cancer diagnosis, and that the surgi-
cal specimens were all biopsies and excluded transurethral 
resections. “Date of cohort entry” was defined as the date of 
initial benign prostatic biopsy; “date of case diagnosis” was 
the date of first cancer- positive tissue specimen or the date a 
clinician first reported a clinical diagnosis of prostate cancer. 
Patients diagnosed with prostate cancer less than 1 year from 
date of initial biopsy were ineligible for the study. Within the 
cohort, we identified 725 potentially eligible cases diagnosed 
with prostate cancer prior to December 2012.
K E Y W O R D S
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Incidence density sampling was used to select matched 
controls with replacement from all cohort members at risk 
at the time of case occurrence. Controls were randomly se-
lected from among those cohort members who were free 
of prostate cancer at a follow- up duration greater than or 
equal to the time between cohort entry and diagnosis of the 
matched case. Matching criteria included age at entry into 
cohort (±2  years), date of entry into cohort (±  2  years), 
and African American (AA) or White race. We were able 
to match 673 case- control pairs with prostate biopsy tis-
sue available for assaying. The remaining 52 cases could 
not be matched to form an eligible case/control pair due to 
(1) pathologic reexamination of recut “benign” biopsy at 
the time of the cohort entry detected malignancy (n = 19, 
36.5%); (2) medical record review found prior history of 
prostate (n  =  5, 9.6%) or other types of cancer (n  =  4, 
7.7%); (3) no eligible controls could be matched to a case 
(n  =  14, 26.9%); (4) lack of analyzable prostate tissue 
(n = 8, 15.4%); and (5) unable to confirm incident prostate 
cancer diagnosis (n = 2, 3.8%).
2.2 | Pathologic review
All benign tissue specimens were screened for the presence 
of cancer and inflammation by a genitourinary patholo-
gist (NG or SW) blinded to disease progression. For cases 
with varying intensity of inflammatory infiltrate, the high-
est grade was recorded. The extent of inflammation was 
scored as focal (<10% of specimen), multifocal (10%– 50% 
of specimen), or diffuse (>50% of specimen). Specimens 
with evidence of nonreported malignancy were reviewed 
by a second pathologist (NG or SW) before exclusion from 
the sample. Acute and chronic inflammation were evalu-
ated by distribution of polymorphonuclear (PMN) and 
mononuclear cells (MNCs), respectively,27 with inflamma-
tion for each specimen scored by grade (mild, moderate, 
severe) and extent (focal: <10% of specimen; multifocal: 
10%– 50% of specimen; or diffuse: >50% of specimen) 
for both cell types.28 Figure S1 shows representative im-
ages of acute inflammation and different grades of chronic 
inflammation.
2.3 | Specimen processing and 
immunohistochemistry
Formalin- fixed biopsy specimens embedded in paraffin 
blocks were procured from Henry Ford Hospital bioreposi-
tory. We randomly selected a subset of blocks for each case 
from blocks with available tissue cores. The number of biopsy 
cores analyzed ranged from one to 14 with 50% or more of the 
available cores examined for 80% of the study participants. 
For each block, serial sections at 5- micron thickness were 
cut. The middle section was stained with hematoxylin and 
eosin and a pathologist (NG or SW) confirmed the tumor/
benign status of the specimen and did histopathologic as-
sessment of atrophy and inflammation. An unstained section 
from each specimen was used for double staining of NF- κB 
and GDF- 15 using a modified immunohistochemistry (IHC) 
protocol. To control for variation in experimental conditions, 
matched case- control pair biopsy specimens were processed 
on the same IHC run. Prostatectomy tissue was included as 
a positive control, and primary antibody was omitted as a 
negative control.
Slides were dried 30 min at 60°C, then deparaffinized 
down to deionized water. Antigen retrieval was performed 
on a PT Link (Dako) by preheating Target Retrieval Solution 
to 60°C and heating for 20 min at 97°C in pH =9 (Dako). 
Slides were washed with buffer for 5  min. Slides were 
stained on an automated Dako Autostainer (Agilent) with 
two drop zones at 150 µl each. Dual endogenous enzyme 
block was used (Dako), then protein block (Background 
Punisher, Biocare). Antibodies used were goat polyclonal 
antibody to GDF- 15 (catalog AF957, R&D Systems, 
Minneapolis) and rabbit monoclonal antibody to NF- κB 
p65 (clone D14E12, Cell Signaling Technologies, Beverly, 
MA). Antibodies were applied as a GDF- 15 (1:900)/NF- κB 
(1:1400) cocktail, for a 20- min incubation. The secondary 
antibody was Mach2 double stain 2 (Biocare) micropoly-
mers consisting of anti- goat and anti- rabbit conjugated to 
horseradish peroxidase and alkaline phosphatase respec-
tively. Secondary antibodies were applied for 20 min fol-
lowed by two buffer washes. Substrate chromogens were 
FLEX DAB for horseradish peroxidase and Ferangi Blue for 
alkaline phosphatase and applied for 10 min. Background 
was stained with hematoxylin Dako FLEX, and slides were 
rinsed with deionized water and oven dried 15 min. Cover 
slipping was with xylene- substitute mounting medium 
EcoMount (Biocare).
2.4 | Stained slide processing and 
image analysis
Whole slide scanning of NF- κB and GDF- 15 stained 
matched benign biopsy slides was performed on two 
different platforms— Ventana iScan HT slide scanner 
(Roche Diagnostics) and/or Aperio CS2 Scanner (Leica 
Biosystems) at 40× magnification. All case- control pairs 
were scanned for further staining analysis on the same plat-
forms to avoid any bias due to different scanning modali-
ties. The whole slide scanned image was further processed 
using the open source image analysis software QuPath 
v0.2.3.29 All glandular and periglandular regions immedi-
ately adjacent to the glands were annotated after excluding 
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tissue regions with any tissue folding or other processing/
staining artefacts. The annotated regions were then pro-
cessed using a customized script developed to estimate the 
intensity and extent of NF- κB and GDF- 15 expression. The 
tissue and blank areas were separated by overall staining 
optical density (OD) threshold of 0.08. The automated ap-
plication separates positive staining (brown for GDF- 15 
and blue for NF- κB) from the background stain. Percentage 
of positive expression area (PPEA) was quantified as the 
number of positively stained pixels divided by the total 
number of tissue pixels, where the positive pixels are de-
fined as pixels with brown staining OD above threshold 
of 0.15 for GDF- 15 and blue staining OD above thresh-
old of 0.15 for NF- κB. The average expression intensity 
(AEI) was calculated as the mean staining OD of positively 
stained pixels. The log transformed product of PPEA and 
AEI, log(PPEA*AEI), was used as the marker expression 
level of a subject.
2.5 | Statistical analysis
Conditional logistic regression analyses were used to esti-
mate odds ratios (ORs) for prostate cancer incidence dur-
ing follow- up. One- to- one matching controlled for age and 
race. Initial unmatched analyses examined the correlation 
between GDF- 15 and NF- κB expression as well as the as-
sociation of each marker with race and different histologic 
features. These unmatched analyses also included a covari-
ate for IHC batch to control for experimental variation. 
Risk modeling of expression levels was done on both on 
a continuous and categorical scale— the latter as quartile 
groups. The thresholds for quartile groups were determined 
by the expression levels in control groups for AA and white 
samples separately. Initial univariate models assessed as-
sociations between prostate cancer incidence and marker 
expression level, overall and stratified by race. Next, mul-
tivariable models were fitted to jointly model GDF- 15 and 
NF- κB expression while including variables for PSA level 
at benign biopsy and pathologist- reviewed inflammation 
status. A series of multivariable models were fit stratified 
on race, case aggressive status, age, and time from cohort 
entry to case diagnosis (the latter two were stratified on 
the median). For each model, the statistical significance of 
the linear trend of quartile ORs was tested with a separate 
model where the quartile groupings were modeled as a sin-
gle trend variable coded as 1 (lowest quartile) through 4 
(highest quartile). A secondary analysis explored nonlin-
ear associations between marker expression and prostate 
cancer risk. In this modeling approach, polynomials were 
used to represent nonlinear relationships that included test-
ing higher order risk terms. The same covariates that were 
adjusted for in the primary analysis were included in these 
nonlinear models. A likelihood ratio χ2 test was used to 
evaluate the significance of nested models.
3 |  RESULTS
3.1 | Study sample
Among the eligible 673 case- control pairs, we were able to 
successfully stain, scan, and image process NF- κB and GDF- 
15 stained slides for 508 case- control pairs. An additional 
five pairs were removed because of incomplete covariate 
data or lack of prostate tissue on the IHC slide, resulting 
in a final analytic dataset of 503 case- control pairs. Most 
pairs were excluded due to tissue loss during the multi- stain 
process— a comparison of the cases in these excluded pairs 
(n = 170) versus those in the analytic dataset demonstrated 
little evidence of bias in terms of the cases that were selected 
for analysis with date of cohort entry the only variable that 
was significantly different between excluded cases and those 
in the analytic sample (Table S1). Excluded cases had biopsy 
specimens that were on average about a year older, which 
may explain why staining failed on these specimens. Table 1 
shows the demographic and clinical characteristics of the an-
alytic study sample that comprised 503 matched case- control 
pairs. Cases were 46% AA with an average age of 64.5 years 
at cohort entry. Date of cohort entry ranged from 1990 to 
2011; the median date of cohort entry was February 1997 for 
cases and March 1997 for controls. By design, cases were di-
agnosed with cancer at least 1- year post- cohort entry; the me-
dian time to cancer diagnosis was 6.34 years, with the longest 
interval from cohort entry to diagnosis being 18 years. Cases 
had a significantly higher PSA level at time of cohort entry 
but had a similar number of PSA tests between cohort entry 
and diagnosis (reference date for controls). Most cases were 
diagnosed with clinical stage 1 (74.3%) and 2 (23.5%) tumors. 
Approximately 26% of cases had advanced tumor grade, de-
fined as either Gleason score 7 with a primary grade 4 (that 
is, International Society of Urological Pathology grade group 
3), or higher. Both chronic and acute inflammation were 1– 2 
percentage points higher in controls compared to cases.
3.2 | NF- κB and GDF- 15 expression in 
benign prostate biopsies
Some level of NF- κB p65 expression was quantifiable in 
most benign prostatic biopsies, with the strongest expression 
observed primarily in the basal cells of prostate glandular 
epithelium (Figure 1A and Figure S3). GDF- 15 expression 
was also quantifiable in most biopsy specimens, however 
GDF- 15 expression tended to be more localized and gener-
ally restricted to the luminal aspect of glandular epithelium 
   | 5RYBICKI et al.
(Figure  1A and Figure  S2). Isolated dark- staining cells 
within the gland epithelium expressing GDF- 15 were also 
observed in a subset of the stained slides (Figure S2). When 
we analyzed the coexpression of NF- κB and GDF- 15 in 
separately annotated regions, a strong positive correlation 
(r  =  0.39; p  <  0.0001) between the two markers emerged 
that was independent of race (Figure 1B). Expression of both 
GDF- 15 (Figure 1C) and NF- κB (Figure 1D) was lower in 
AA men with racial differences in expression of both mark-
ers independent of case/control status. After adjusting for 
imaging platform and experimental batch, NF- κB expression 
showed the strongest racial disparity (−5.41 ± 1.59 for AA 
vs. −4.79 ± 1.49 for White men; p = 0.0003), whereas for 
GDF- 15 expression the racial disparity in expression was 
less pronounced (−7.12 ± 1.40 for AA vs. −6.70 ± 1.38 for 
White men; p = 0.003).
Both NF- κB and GDF- 15 expression levels were con-
trasted with prostatic inflammation (Figure  2), but only 
GDF- 15 expression significantly varied (Figure  2C,D). In 
prostatic biopsy specimens with chronic inflammation, GDF- 
15 expression was significantly lower than in biopsies with no 
inflammation (p = 0.002). Examining the grade and extent of 
chronic inflammation, GDF- 15 expression showed an inverse 
linear trend with worsening inflammation (p  =  0.00004). 
GDF- 15 expression was reduced by about five percent in 
specimens with at least a moderate grade or extent of inflam-
mation compared to specimens with no inflammation.
3.3 | NF- κB and GDF- 15 expression and 
prostate cancer risk
Examination of NF- κB and GDF- 15 expression levels by case- 
control status showed slightly lower expression levels of NF- κB 
in cases compared to controls (−4.81 ± 1.87 vs. −4.68 ± 1.80; 
p = 0.04), and a higher, albeit non- significant, level of GDF- 15 
T A B L E  1  Characteristics of analytic sample at baseline (503 matched pairs)
Variable Response Cases Controls
P 
value
Racea White 271 (54.0%) 271 (54.0%) — 
African- American 232 (46.0%) 232 (46.0%)
Mean age at cohort entry (years)a  ± SD 64.5 ± 7.3 64.5 ± 7.3 — 
Median date at cohort entrya 02/13/1997 03/17/1997 — 
Median time to case diagnosis (years)a 6.34 — — 
Mean Serum PSA at cohort entry (ng/ml) ± SD 6.23 ± 0.28 5.42 ± 0.24 0.005




None 213 (42.3%) 197 (39.2%) 0.33
Chronic only 258 (51.3%) 263 (52.3%)
Chronic and/or Acute 32 (6.4%) 43 (8.5%)
Mean Serum PSA at time of case diagnosis (ng/
ml) ± SD
24.6 ± 8.2 — 
Tumor stageb 1 374 (74.3%) — 
2 118 (23.5%) — 
3 7 (1.4%) — 
4 4 (0.8%) — 
Gleason grade groupc 1 232 (46.1%) — 
2 116 (23.1%) — 
3 47 (9.3%) — 
4 55 (10.9%) — 
5 32 (6.4%) — 
Abbreviations: PSA, prostate specific antigen; SD, standard deviation.
aMatching factor. 
bClinical Stage unless missing, then Pathologic Stage reported. 
cTumor grade based on prostatectomy and if missing, biopsy; 21 cases had missing tumor grade. 
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expression in cases compared to controls. Case- control differ-
ences in NF- κB expression were most prominent in white men 
(−4.63 ± 1.80 vs. −4.42 ± 1.54; p = 0.03). When we modeled 
co- expression of both markers, the negative prostate cancer 
risk association with NF- κB expression remained (OR =0.87; 
95% confidence interval [CI] =0.77– 0.99; p = 0.03) and there 
was also a nominal positive association between case status and 
GDF- 15 expression (Table 2). A slightly stronger negative as-
sociation of NF- κB expression with case status was observed 
in White vs. AA men (OR =0.83 vs. 0.93) while the adjusted 
positive association of GDF- 15 expression was slightly higher 
in AA men (OR =1.09 vs. 1.03).
The expression of NF- κB was next modeled in quar-
tiles with the lowest expression level of each marker serv-
ing as the reference category (Table 3; see Figure S3 for 
representative staining by expression quartile). For the full 
sample, in the adjusted model the OR for the highest level 
of NF- κB expression was 0.51 and nominally statistically 
significant (p = 0.03). Higher expression levels of GDF- 
15 in the adjusted model showed a OR in the 4th quartile 
marginally higher than one but not statistically significant 
nor did the quartile ORs increase in a linear fashion. The 
inverse association of NF- κB expression with prostate 
cancer was stronger and remained statistically significant 
in AA men.
3.4 | Stratified analyses
Table 4 shows stratified analyses by a case aggressive sta-
tus, age and time between cohort entry and case diagnosis. 
Negative associations of NF- κB expression with case status 
were more prominent for non- aggressive cases— the OR for 
the highest (4th) expression quartile was 0.42 (95% CI =0.21– 
0.86) and the p for trend of the ORs was 0.03. For GDF- 15 
expression, associations with prostate cancer risk did not 
appear to differ by disease aggressive status. Stratifying the 
case sample by age yielded the most disparate associations. 
Negative associations with NF- κB expression and positive 
associations with GDF- 15 expression were observed only in 
older cases. In the highest quartile of NF- κB expression, the 
OR for prostate cancer risk was 0.32; 95% CI =0.13– 0.78; 
p = 0.01. In the highest quartile of GDF- 15 expression, the 
OR for prostate cancer risk was 1.77; 95% CI =1.00– 3.12; 
p = 0.05. The linear trend of decreasing ORs for NF- κB ex-
pression was statistically significant (p = 0.01). Stratifying 
by time to diagnosis revealed a slightly stronger negative 
association between NF- κB expression and prostate cancer 
risk (OR for the highest quartile  =0.33; 95% CI  =0.13– 
0.80; p = 0.01) in the case- control pairs with longer follow-
 up. While GDF- 15 expression appeared to have a stronger 
association with prostate cancer risk in this stratum, the 
F I G U R E  1  NF- κB and GDF- 15 co- expression. (A) Representative picture of NF- κB (blue) and GDF- 15 (brown) staining in benign prostate 
glandular epithelium. (B) Scatter plot of NF- κB and GDF- 15 expression levels in all prostate biopsy specimens (n = 820) and distribution by race 
of (C) NF- κB and (d) GDF- 15 expression in prostate biopsy specimens (n = 450 Whites; n = 370 African Americans)
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differences in effect estimates were not as striking. Analyses 
further stratified by race were also done for these three strata 
(Tables  S2– S4). Among less aggressive cases in AA men, 
NF- κB and GDF- 15 inverse associations with prostate cancer 
were most stark— the OR for a linear trend in NF- κB asso-
ciation was 0.57, whereas the comparable OR for GDF- 15 
was 1.15 (Table S2). Associations of higher GDF- 15 expres-
sion with prostate cancer in older men (Table S3) was nota-
bly stronger in AA men (OR for the highest quartile =3.36; 
95% CI =1.28– 8.82; p = 0.01). The negative association of 
NF- κB expression with prostate cancer risk for cases with 
longer follow- up (Table  S4) was most prominent in white 
F I G U R E  2  NF- κB and GDF- 15 expression by inflammation status. (A) NF- κB expression by chronic and acute inflammation status 
(p = 0.76); (B) GDF- 15 expression by chronic and acute inflammation status (p = 0.001); (C) NF- κB expression by extent and grade of chronic 
inflammation (p = 0.62); (D) GDF- 15 expression by extent and grade of chronic inflammation (p < 0.0001)
Variable
Unadjusted models Adjusted modelsa 
Odds ratio





Full Sample (n = 503 pairs):
NF- κB 0.89 (0.79– 1.00) 0.04 0.87 (0.77– 0.99) 0.03
GDF−15 1.00 (0.94– 1.12) 0.56 1.06 (0.96– 1.17) 0.27
Whites (n = 271 pairs):
NF- κB 0.84 (0.71– 0.99) 0.03 0.83 (0.70– 0.98) 0.03
GDF−15 0.96 (0.85– 1.08) 0.50 1.03 (0.90– 1.17) 0.70
African Americans (n = 232 pairs):
NF- κB 0.94 (0.81– 1.11) 0.47 0.93 (0.78– 1.10) 0.39
GDF−15 1.06 (0.92– 1.21) 0.44 1.09 (0.94– 1.27) 0.24
Abbreviations: CI, confidence interval; n, number.
aAdjusted models have covariates for PSA, inflammation, and both markers (NFκB and GDF15). 
T A B L E  2  Modeling of NF- κB and 
GDF- 15 expression and prostate cancer risk 
in matched case- control pairs
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men (OR for the highest quartile =0.26; 95% CI =0.08– 0.82; 
p = 0.03).
3.5 | Nonlinear models
The modeling of NF- κB and GDF- 15 risk by quartiles of 
expression suggested risk may increase in a nonlinear fash-
ion; therefore, we tested a series of polynomial models that 
included higher order risk terms for both NF- κB and GDF- 
15 expression. Including covariables for prostate inflam-
mation and PSA as well as the other marker, we first tested 
nested models with a second- order and third- order risk term 
for NF- κB expression, but neither of these models signifi-
cantly improved the fit over the simpler nested model. In a 
similar fashion, we tested the same nested models for GDF- 
15 expression. Here, we found that the addition of a second 
order term for GDF- 15 expression significantly improved the 
Variable
Unadjusted models Adjusted modelsa 
Odds ratio (95% 
CI) P value




Full sample (n = 503 pairs):
NF- κB
2nd quartile 0.66 (0.44– 0.99) 0.04 0.62 (0.40– 0.94) 0.03
3rd quartile 0.72 (0.44– 1.16) 0.17 0.70 (0.42– 1.15) 0.16
4th quartile 0.53 (0.30– 0.94) 0.03 0.51 (0.28– 0.92) 0.03
Linear trend 0.83 (0.68– 1.00) 0.04 0.81 (0.67– 0.99) 0.04
GDF−15
2nd quartile 0.77 (0.54– 1.10) 0.16 0.83 (0.57– 1.20) 0.31
3rd quartile 0.91 (0.64– 1.29) 0.58 1.00 (0.69– 1.45) 0.99
4th quartile 1.05 (0.72– 1.51) 0.81 1.24 (0.83– 1.83) 0.29
Linear trend 1.03 (0.92– 1.16) 0.62 1.09 (0.96– 1.23) 0.19
Whites (n = 271 pairs):
NF- κB
2nd quartile 0.67 (0.39– 1.13) 0.14 0.66 (0.38– 1.14) 0.14
3rd quartile 0.80 (0.46– 1.39) 0.43 0.80 (0.45– 1.43) 0.45
4th quartile 0.61 (0.31– 1.21) 0.16 0.62 (0.30– 1.27) 0.19
Linear trend 0.88 (0.71– 1.09) 0.25 0.88 (0.70– 1.11) 0.29
GDF−15
2nd quartile 0.70 (0.43– 1.15) 0.16 0.75 (0.45– 1.25) 0.27
3rd quartile 0.95 (0.59– 1.54) 0.84 1.06 (0.63– 1.77) 0.83
4th quartile 0.84 (0.52– 1.36) 0.48 1.01 (0.60– 1.70) 0.98
Linear Trend 0.98 (0.84– 1.14) 0.79 1.04 (0.88– 1.23) 0.64
African- Americans (n = 232 pairs):
NF- κB
2nd quartile 0.60 (0.31– 1.16) 0.13 0.52 (0.26– 1.04) 0.07
3rd quartile 0.48 (0.18– 1.27) 0.14 0.42 (0.15– 1.17) 0.10
4th quartile 0.33 (0.11– 1.02) 0.05 0.29 (0.09– 0.96) 0.04
Linear trend 0.68 (0.47– 0.99) 0.05 0.65 (0.44– 0.97) 0.03
GDF−15
2nd quartile 0.85 (0.51– 1.44) 0.55 0.91 (0.53– 1.58) 0.74
3rd quartile 0.85 (0.51– 1.43) 0.54 0.89 (0.52– 1.53) 0.67
th quartile 1.48 (0.82– 2.65) 0.19 1.73 (0.92– 3.25) 0.09
Linear trend 1.10 (0.92– 1.32) 0.28 1.14 (0.95– 1.38) 0.17
Abbreviation: CI, confidence interval.
aAdjusted models have covariates for PSA, inflammation and both markers (NF- κB and GDF- 15). 
T A B L E  3  Modeling of NF- κB and 
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fit of the model (p  =  0.02); however, adding a third- order 
term did not significantly improve the fit. Risk estimates for 
the model with the second- order risk term over the range of 
GDF- 15 expression both for the full sample as well as the 
race- stratified samples are depicted in Figure 3. In only AA 
men was a second- order polynomial model a better fit to the 
GDF- 15 expression data (p = 0.04). Exploring further subsets 
of the data with this same nonlinear model, statistically sig-
nificant first- order and second- order GDF- 15 risk estimates 
were found for subsamples defined by aggressive disease 
Variables
Odds ratio (95% 
CI) P value




Aggressive diseasea No (n = 325 pairs) Yes (n = 178 
pairs)
NF- κB
2nd quartile 0.51 (0.31– 0.84) 0.01 1.01 (0.43– 2.38) 0.98
3rd quartile 0.70 (0.38– 1.28) 0.25 0.79 (0.32– 1.95) 0.61
4th quartile 0.42 (0.21– 0.86) 0.02 0.76 (0.25– 2.30) 0.63
Linear trend 0.77 (0.61– 0.98) 0.03 0.90 (0.63– 1.30) 0.58
GDF−15
2nd quartile 0.86 (0.54– 1.36) 0.52 0.74 (0.39– 1.41) 0.36
3rd quartile 1.18 (0.74– 1.89) 0.48 0.82 (0.45– 1.51) 0.53
4th quartile 1.16 (0.71– 1.88) 0.55 1.41 (0.71– 2.82) 0.33
Linear trend 1.08 (0.93– 1.26) 0.30 1.10 (0.89– 1.37) 0.38




2nd quartile 0.75 (0.41– 1.38) 0.35 0.49 (0.26– 0.92) 0.03
3rd quartile 0.70 (0.35– 1.41) 0.32 0.70 (0.33– 1.51) 0.37
4th quartile 0.79 (0.35– 1.81) 0.58 0.32 (0.13– 0.78) 0.01
Linear trend 0.92 (0.70– 1.21) 0.54 0.72 (0.54– 0.97) 0.03
GDF−15
2nd quartile 0.47 (0.27– 0.84) 0.01 1.30 (0.78– 2.19) 0.32
3rd quartile 0.90 (0.52– 1.56) 0.70 0.99 (0.58– 1.68) 0.97
4th quartile 0.84 (0.47– 1.51) 0.57 1.77 (1.00– 3.12) 0.05
Linear trend 1.03 (0.86– 1.24) 0.74 1.14 (0.96– 1.36) 0.14





2nd quartile 0.58 (0.32– 1.05) 0.07 0.63 (0.34– 1.18) 0.15
3rd quartile 0.77 (0.38– 1.53) 0.45 0.57 (0.27– 1.20) 0.14
4th quartile 0.71 (0.31– 1.61) 0.41 0.33 (0.13– 0.80) 0.01
Linear trend 0.90 (0.69– 1.18) 0.44 0.70 (0.52– 0.94) 0.02
GDF−15
2nd quartile 0.85 (0.51– 1.41) 0.52 0.80 (0.46– 1.39) 0.42
3rd quartile 1.01 (0.60– 1.68) 0.98 0.97 (0.56– 1.67) 0.90
4th quartile 0.94 (0.54– 1.62) 0.82 1.53 (0.84– 2.76) 0.16
Linear trend 1.00 (0.84– 1.18) 0.98 1.17 (0.97– 1.41) 0.09
Note:: All models have covariates for PSA, inflammation and both markers (NF- κB and GDF- 15)
Abbreviation: CI, confidence interval.
aAggressive disease defined as Gleason group 3 or higher or PSA ≥20 or Tumor stage 3 or higher. 
bYoung = <65 years old; old =65 years old or greater. 
cEarly = less than 3.7 years; late =3.7 years or greater. 
T A B L E  4  Stratified models of NF- κB 
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(p = 0.004), younger age (p = 0.01) and in case- control pairs 
with longer follow- up (p = 0.03) (Figure S4).
4 |  DISCUSSION
In a large, racially heterogeneous cohort of men with a be-
nign prostatic biopsy, we observed suggestive associations 
of decreased NF- κB and increased GDF- 15 expression in 
benign prostate with subsequent prostate cancer detection. 
These associations were more pronounced when stratifying 
case- control pairs by age or case aggressive status. Opposite 
associations of NF- κB and GDF- 15 expression with prostate 
cancer risk were observed despite the finding that expression 
of these two proteins positively correlated with each other. 
Overall, GDF- 15 expression was lower in AA benign pros-
tate compared with benign prostate of white men which is 
consistent with the known effect of Vitamin D to upregu-
late GDF- 15,30 along with the tendency of AA men to have 
a relative Vitamin D deficiency. In a separate study focused 
on prostate tumor and adjacent benign tissue by Iczkowski 
et al.,31 our team found strong stage- wise upregulation of 
GDF- 15 immunostaining in AA men. Since our analysis of 
benign biopsies shows a lower GDF- 15 expression in AA 
men, this implies an even greater upregulation from benign 
glands to intraprostatic tumor (pathologic stage 2) to extra- 
prostatic tumor (higher stages), in which GDF- 15 is highest 
in AA men. Moreover, in benign biopsies, increased GDF- 15 
expression had a suggestive association with prostate cancer 
in AA men, particularly when modeling GDF- 15 in a nonlin-
ear fashion that allowed for a thresholding of GDF- 15 risk at 
the highest expression levels. This suggests a greater modu-
lation of GDF- 15 may occur during carcinogenesis in AA 
men.
A previous study showed that in human prostate GDF- 
15 suppresses the activity of NF- κB, indicating a tumor- 
suppressing quality, but it may also preferentially inhibit 
M1 macrophage formation, indicating a pro- tumorigenic 
quality.24 During the course of prostatic carcinogenesis, M1 
macrophages transform into a M2 phenotype, contributing 
to an immunosuppressive microenvironment that promotes 
tumor growth and metastasis.32 Recent evidence suggests 
that macrophages acquiring M2- like characteristics may up-
regulate GDF- 15 expression in human cancer.33 In a study of 
men who developed prostate cancer and were subsequently 
followed for biochemical recurrence, we measured the co- 
expression of M1/M2 macrophages and GDF- 15 in paired 
prostate specimens that reflected both the pre- and post- 
malignant states.34 GDF- 15 expression showed a pattern in 
which the highest mean levels were observed in the normal 
prostatic glands adjacent to tumor. Moreover, men in whom 
the differential GDF- 15 expression was highest between 
tumor and normal adjacent glands had the lowest risk of 
biochemical recurrence. This suggests that while increased 
GDF- 15 expression may be a harbinger of prostate cancer 
development, overexpression of GDF- 15 may also serve a 
tumor suppressive function in terms of limiting the spread 
of cancer. Clearly, a high degree of variation in GDF- 15 
expression exists in the different stages of prostate cancer,21 
and studies of prostate cancer field cancerization 35,36 sug-
gest that GDF- 15 may be overexpressed in tumor- adjacent 
normal glands, and this might explain the association we 
found between GDF- 15 expression and elevated prostate 
cancer risk in AA men.
NF- κB can activate and regulate the expression of many 
inflammatory factors, which makes it the key promoter of 
the inflammatory response.37 Infection or hypoxia activates 
NF- κB, which is inactive in cells, and activates inflamma-
tory genes, induces the upregulation of cytokines, adhe-
sion molecules, and vasoactive regulators and increases 
the concentration of further downstream cytokines such 
as tumor necrosis factor- α (TNF- α), interleukin- 6 (IL- 6), 
interleukin- 8 (IL- 8), and others.38 Similar to the few stud-
ies that have demonstrated NF- κB expression in benign 
prostate,15,19,39 observable NF- κB expression in our benign 
biopsy specimens was primarily cytoplasmic and in glan-
dular basal cells suggesting that the NF- κB expression de-
tected was the inactive form of the enzyme. While our dual 
staining assay could possibly reduce the antigenicity of the 
monoclonal antibody to NF- κB p65, given that the NF- κB 
F I G U R E  3  Nonlinear modeling of GDF- 15 expression and prostate cancer risk. Estimates for the following nonlinear model of prostate cancer 
risk: β0+ PSA x β1 + prostatic inflammation x β2 + NF- κB expression x β3 + GDF- 15 expression x β4 + (GDF- 15 expression)
2 x β5 (PSA, prostatic 
inflammation and NF- κB expression set at mean levels) for A) Full sample (n = 503 case- control pairs); B) Whites (n = 271 case- control pairs) 
and; C) African American (n = 232 case- control pairs)
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expression we were able to quantify in the majority of be-
nign prostate specimens had a similar pattern of intensity 
and localization as has been previously reported in benign 
prostate 15,19,39 would suggest reduced antigenicity was not 
an issue. In prostate cancer, NF- κB becomes constitutively 
activated in a high proportion of castration- resistant pros-
tate cancers,13,40 but the active form of the enzyme is also 
detectable in early prostate carcinogenesis.41,42
Previous studies suggested NF- κB exerts a reciprocal 
interaction with GDF- 15.24,43 Lambert et al. used a firefly 
luciferase construct to show that expression of the NF- 
κB target, IL- 8, was downregulated by GDF- 15 in PC3 
cells.24 GDF- 15 also inactivates NF- κB signaling in den-
dritic cells, enabling induction of immune tolerance after 
heart transplantation.43 In our data, NF- κB and GDF- 15 
expression were positively correlated, and expression of 
GDF- 15 was negatively correlated with chronic inflam-
mation levels. While these results contradict what has 
been observed in the tumor environment, both NF- κB 
26,39,44 and GDF- 15 26,34 expression levels are known to 
change as a result of malignant transformation in pros-
tate and as we and others have previously shown, inflam-
mation in benign prostate reduces the risk of subsequent 
cancer.6,7,9 Furthermore, the results of Ratnam et al., that 
show in pancreatic cancer NF- κB is a direct regulator of 
GDF- 15, provide a possible mechanistic explanation for 
the inverse association of GDF- 15 and chronic inflamma-
tion in our data. In the former pancreatic cancer model, 
NF- κB- activated GDF- 15 suppresses macrophage cyto-
toxic activity. This model of early cancer immune sur-
veillance could also occur in prostate cancer and may 
explain the correlation we observe between NF- κB and 
GDF- 15 and the negative correlation of the latter with 
chronic inflammation.
NF- κB expression levels are known to steadily increase 
as cancer progresses,26,39,44 but no prior study has examined 
the association of NF- κB expression in benign prostate and 
subsequent prostate cancer risk. Others, including our group, 
have found racial differences in NF- κB expression and pros-
tate cancer aggressiveness.45 While we found NF- κB ex-
pression was positively associated with tumor grade only in 
AA men,31 Hu et al.45 found the opposite albeit with a much 
smaller sample. Studies have consistently shown NF- κB ex-
pression levels are associated with poor clinical outcome in 
prostate cancer patients,17,46- 48 but no reports of racial dif-
ferences in these associations exist. In general, the ORs of 
the association of prostate cancer risk with NF- κB expression 
were less than one and similar in magnitude for both races. 
In stratified analyses, however, AA men had greater dispar-
ity of NF- κB expression associations with prostate cancer by 
disease aggressive status (NF- κB decreased risk for nonag-
gressive disease but showed a suggestive positive association 
with aggressive disease) and age (NF- κB decreased risk for 
older cases but showed a suggestive positive association with 
prostate cancer for younger cases). Among White men, NF- 
κB expression appeared to have a stronger negative associ-
ation with prostate cancer for cases that developed later in 
follow- up.
The findings of our study may not be generalizable to all 
men. By virtue of having a prostate biopsy, cohort members 
were at elevated risk for prostate cancer and therefore cannot 
be considered representative of all men in the same age and 
race demographic. We excluded patients diagnosed with can-
cer within a year after cohort entry to minimize the chance 
of undetected prostate cancer at time of biopsy. Nonetheless, 
based on the age and risk profile of men in our cohort some 
likely had synchronous prostate cancer that was missed on 
biopsy. Despite the inherent shortcomings of a retrospective 
cohort design, embedding the cohort within a single health 
system permitted efficient sampling and complete incident 
case detection. Our nested case- control sample also gave 
us the ability to estimate the prostate cancer risk associated 
with NF- κB and GDF- 15 expression in benign prostate, 
which apart from unique studies such as the Prostate Cancer 
Prevention Trial,49 could not be carried out in a prospective 
setting.
In summary, NF- κB and GDF- 15 expression appear to 
exert opposite effects on prostate tumor development, espe-
cially in AA men. The interplay of prostatic inflammation 
with NF- κB and GDF- 15 expression in early prostate can-
cer development is unclear from our study results, although 
our findings suggest GDF- 15 may repress chronic inflam-
mation in the benign prostate. There was no suggestion of 
a modifying effect of inflammation on prostate cancer risk 
associated with either NF- κB or GDF- 15 expression. Much 
like the suspected diverse role of GDF- 15 in prostate carcino-
genesis, NF- κB may exert differing effects along the contin-
uum of prostate tumor development. While our study sheds 
some light on the effect NF- κB and GDF- 15 may have on 
prostate tumor development in the time just before malignant 
transformation, more modeling of the premalignant setting is 
needed to determine the dynamic changes in inflammatory 
mediators that initiate and support malignancy in prostate.
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